Subscribe, the financial lines managing general agent (MGA) within Acies MGU, has secured a £5 million binder from Fortegra Insurance UK (FIUK) to support its UK micro and SME professional indemnity (PI) book.
FIUK is a subsidiary of global specialty insurer Fortegra, part of South Korea’s DB Insurance. It holds an AM Best financial strength rating of A (Excellent).
The capacity will also support new products Subscribe plans to launch in 2026 and 2027. These include specialist medical malpractice and healthcare products, alongside other niche propositions.
Subscribe launched in November 2025 as a Lloyd’s-backed MGA. It offers PI, directors’ and officers’ and management liability cover, aimed mainly at SME and mid-corporate clients in the UK and internationally.
When David Eynon was appointed managing director in August, Insurance Business noted it was not yet clear whether Subscribe’s capacity would extend beyond its existing Lloyd’s and A-rated backing. The Fortegra binder answers that, adding company market capacity dedicated to the smaller end of its PI book.
“Long-term capacity partnerships are fundamental to the success of any specialist MGA,” said Eynon.
He said Subscribe’s focus was on building sustainable underwriting propositions that solve genuine market problems, backed by capacity providers with a long-term outlook.
The deal comes as Subscribe prepares to launch several new specialist facilities over the coming months. They will take it beyond traditional financial lines into adjacent specialist markets, where it believes brokers need more underwriting expertise and flexibility.
Medical malpractice and healthcare are the first areas named. Both are classes where smaller healthcare providers and practitioners can struggle to find appetite, particularly outside the large hospital and group market.
For brokers placing micro and SME PI, the binder adds another A-rated option, in a class where competition is already intense and rates are under pressure. A dedicated company market binder for smaller risks may suit brokers who want faster, delegated decisions on low-premium business rather than going to the London market.
The bigger interest is in what comes next. If Subscribe’s medical malpractice and healthcare products arrive as planned, brokers with clinics, care providers and independent practitioners on their books could gain a specialist new market for risks that are often hard to place.
At £5 million, the binder is modest, which suggests a measured build rather than an aggressive push. Brokers will want to see how quickly Subscribe can turn its new facilities into appetite they can actually use.
